Pan-AKT Inhibitor Capivasertib With Docetaxel and Prednisolone in Metastatic Castration-Resistant Prostate Cancer
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Disclosure statements are available on the authors' profiles:
Journal of Clinical Oncology
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Pan-AKT Inhibitor Capivasertib With Docetaxel and Prednisolone in Metastatic Castration-Resistant Prostate Cancer: A Randomized, Placebo-Controlled Phase II Trial (ProCAID)
J. Clin. Oncol 2020 Dec 16;[EPub Ahead of Print], SJ Crabb, G Griffiths, E Marwood, D Dunkley, N Downs, K Martin, M Light, J Northey, S Wilding, A Whitehead, E Shaw, AJ Birtle, A Bahl, T Elliott, C Westbury, S Sundar, A Robinson, S Jagdev, S Kumar, C Rooney, C Salinas-Souza, C Stephens, V Khoo, RJ JonesFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Advanced Prostate Cancer Center of Excellence
Visit our Advanced Prostate Cancer Center of Excellence for additional, in-depth coverage.